• Backed LLP made an equity investment in AI-driven fungal drug discovery startup Novogaia in January 2026.
• The transaction backed founder Tess Bevers as Novogaia develops medicines from fungi using transformer-based AI with mass spectrometry.
• Novogaia’s lead program targets an innate immunity pathway in inflammatory disease, aiming to improve dosing versus synthetic drugs in Phase 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Backed LLP published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.